Guzmán PMG, Poletti VED

Language: Spanish
References: 28
Page: s42-47
PDF size: 190.73 Kb.

ABSTRACT

There are descriptions of dermatoses directly associated to the SARS-CoV-2 infection that cannot be classified between the five groups of cutaneous manifestation of the disease. Mucosal damage is not very frequent, but some clinical pictures have been described in the literature. Since we began to learn COVID-19, we realize that this virus has the capability to produce imitation for almost all severe drug reaction manifestations, reactional autoimmune problems or lesions produced by other active viruses. Its physiopathology seems to be complex and involve the defensive mechanisms of the host against the virus. Drug metabolism and intermediate products, can act as antigens or toxic products that can induce strong reactions.

REFERENCES

1. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D et al. Classification of the cutaneous manifestations of Covid-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183 (1): 71-77. doi: 10.1111/bjd.19163.

2. Capocasale G, Nocini R, Faccioni P, Donadello D, Bertossi D, Albanese M et al. How to deal with coronavirus disease 2019: A comprehensive narrative review about oral involvement of the disease. Clin Exp Dent Res. 2021; 7 (1): 101-108. doi: 10.1002/cre2.332.

3. Carreras-Presas M, Amaro SJ, López-Sanchez AF, Jané-Salas E, Somacarrera-Perez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2020; 27 (S3): 710-712. doi/10.1111/odi.1338231.

4. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on "Cutaneous manifestations of COVID-19 a first perspective by Recalcati S. J Eur Acad Dermatol Venereol. 2020; 34 (7): e299-e300. doi/10.1111/jdv16519.

5. Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M, Oral manifestations of Covid-19. Dermatol Ther. 2021; 34 (1): e14578. doi: 10.1111/dth.14578.

6. Díaz RM, Jimenez RA, Villarroel M. Oral manifestations associated with Covid-19". Oral Diseases. 2020. doi: 10.1111/odi.13555.

7. Riad A, Kassem I, Stanek J, Badrah M, Klugarova J, Klugart M. Aphthous stomatitis in COVID-19 patients: case-series and literature review. Dermatol Ther. 2021; 34 (1): e14735. doi: 10.1111/dth.14735.

8. Askin O, Altunkalem RN, Altinisik DD, Uzuncakmak TK, Tursen U, Kutlubay Z. Cutaneous manifestations of hospitalized patients with diagnosis of COVID-19. Dermatol Ther. 2020; 33 (6): e13896. doi: 10.1111/dth.13896.

9. Falkenhain-López D, Agud-Dios M, Ortiz-Romero PL, Sánchez-Velázquez A. COVID-19 related acute genital ulcers. J Eur Acad Dermatol Venereol. 2020; 34 (11): e655-e656. doi: 10.1111/jdv.16740.

10. Pérez-Bartolomé F, Sánchez-Quiroz J. Manifestaciones oftalmológicas del SARS-CoV-2: revisión de la literatura. Arch Soc Esp Oftalmol. 2021; 96 (1): 32-40.

11. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020; 34 (9): e436-e437. doi: 10.1111/jdv.16579.

12. Merhy R, Sarkis AS, Stephan F. Pytiriasis rosea as leading manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2021; 35 (4): e246-e247. doi: 10.1111/jdv/17052.

13. Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus 6, 7 and Epstein Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021; 93 (4): 1850-1851. doi: 10.1002/jmv.26549.

14. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol. 2020; 21 (5): 627-639. doi: 10.1007/s40257-020-00558-4.

15. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-CoV-2. J Eur Acad Dermatol Venereol. 2020; 34 (8): e373-e375. doi: 10.1111/jdv.16623.

16. Mahe A, Birckel E, Krieger S, Merkelen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019. J Eur Acad Dermatol Venereol. 2020; 34 (6): e246-e247. doi: 10.1111/jdv.16471.

17. Chicharro P, Rodriguez-Jimenez P, Muñoz-Aceituno E, De Argila D, Muñoz-Hernandez P, Llamas-Velasco M. SDRIFE-like rash associated with COVID-19, clinicopathological correlation. Australas J Dermatol. 2020; 62 (1): 88-89 doi: 10.1111/ajd.13444.

18. Herman A, Matthews M, Mairlot M, Nobile L, Fameree L, Jacquet M et al. Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19. J Eur Acad Dermatol Venereol. 2020; 34 (12): e768-e700. doi: 10.1111/jdv.16838.

19. Sernicola A, Carnicelli G, Di Fraia M, Chello C, Furlan C, Muharremi R et al. Toxic erythema and eosinophilia associated to tocilizumab therapy in a COVID-19 patient. J Eur Acad Dermatol Venereol. 2020; 34 (8): e368-e370. doi: 10.1111/jdv.16620.

20. Shiohara T, Mizukawa Y. Comment on "Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19": involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity. J Eur Acad Dermatol Venereol. 2021; 35 (2): e98-e100. doi: 10.1111/jdv.16959.

21. Enos T, Jeong HS, Vandergriff T, Jacobe HT, Chong BF. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. Dermatol Ther. 2020; 33 (6): e13834. doi: 10.1111/dth.13834.

22. Robustelli TE, Vezzoli P, Carugno A. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19). J Eur Acad Dermatol Venereol. 2020; 34 (9): e457-e459. doi: 10.1111/jdv.16613.

23. Ayatollahi SA, Robati RM, Kamyab K, Firooz A. Late-onset AGEP-like skin pustular eruption following COVID-19: a possible association. Dermatol Ther. 2020; 33 (6): e14275. doi: 10.1111/dth.14275.

24. Lavery MJ, Bouvier CHA, Thompson B. Cutaneous manifestations of COVID-19 in children (and adults): a virus that does not discriminate. Clin Dermatol. 2020; 14 (40): 14-4.

25. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D'Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet: 2020 Jun 6;395(10239):1771-1778. doi: 10.1016/S0140-6736(20)31103

26. Sokolovsky S, Soni P, Hoffman T, Kahn P, Scheers-Masters J. COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult. Am J Emerg Med. 2021; 39: 253.e1-253.e2.

27. Labe P, Ly A, Sin C, Nasser M, Chapelon-Fromont E, Said PB et al. Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children. J Eur Acad Dermatol Venereol. 2020; 34 (10): e539-e541.

28. Marraha F, Al Faker I, Gallouj S. A review of the dermatological manifestations of coronavirus disease 2019 (COVID-19). Dermatol Research and Practice. 2020; 9360476. doi: 10.1155/2020/9360476.